This report provides comprehensive information on the therapeutic development for Narcolepsy , complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Narcolepsy and special features on late-stage and discontinued projects.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Narcolepsy Overview
- Therapeutics Development
- Pipeline Products for Narcolepsy - Overview
- Pipeline Products for Narcolepsy - Comparative Analysis
- Narcolepsy - Therapeutics under Development by Companies
- Narcolepsy - Therapeutics under Investigation by Universities/Institutes
- Narcolepsy Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Narcolepsy - Products under Development by Companies
- Narcolepsy - Products under Investigation by Universities/Institutes
- Narcolepsy - Companies Involved in Therapeutics Development
Tweets from the Industry
- Bioprojet SCR
- Evotec AG
- Flamel Technologies S.A.
- H.A.C. Pharma
- Jazz Pharmaceuticals Plc
- NLS Pharma Group
- SK Biopharmaceuticals Co., Ltd.
- Taisho Pharmaceutical Holdings Co., Ltd.
- Theranexus SAS
Please find more about Narcolepsy - Pipeline Review, H1 2016 at reports.zursh.com
Click on below items to see free updates about the topic covered.
Click on below items to see free resources and reports about the topic covered.